J&J prostate cancer drug OK'd for wider use in EU
Zytiga, first approved in 2011, is on sale in more than 60 countries, including the U.S.
Cancer of the prostate, the gland surrounding the urethra that produces part of the seminal fluid, can progress so slowly that treatment isn't needed, or it can grow and spread to other body parts very quickly, depending on the individual patient and characteristics of his tumor.
Each year, prostate cancer kills roughly 90,000 men in Europe and about 28,000 in the U.S.
Shares of Johnson & Johnson rose 20 cents to $72.39 in afternoon trading Friday. They are near the high end of their 52-week range of $61.71 to $72.74.
News Photo Galleriesview all
- 30612Oklahoma tornadoes: The 'Big Dog,' the little boy and the hug that triumphs over tragedy
- 15589Bradley Cooper, Zach Galifianakis, Ed Helms drink in success of 'Hangover' series
- 10266Oklahoma tornadoes: Woman meets the military officer who shared the clothes off his back
- 9653Oklahoma tornadoes: Thunder reverses the role, takes a turn at cheering on the community
- 9634Hobby Lobby argues case before federal judges
- 8172Story behind the photo: Family members describe desperate search for one another after EF5 twister
- 8167Blake Shelton's "Healing the Heartland" televised tornado benefit set for Wednesday at Chesapeake Energy Arena